全文获取类型
收费全文 | 2410篇 |
免费 | 130篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 75篇 |
妇产科学 | 50篇 |
基础医学 | 239篇 |
口腔科学 | 34篇 |
临床医学 | 197篇 |
内科学 | 611篇 |
皮肤病学 | 41篇 |
神经病学 | 188篇 |
特种医学 | 75篇 |
外科学 | 486篇 |
综合类 | 13篇 |
预防医学 | 131篇 |
眼科学 | 52篇 |
药学 | 129篇 |
中国医学 | 11篇 |
肿瘤学 | 213篇 |
出版年
2023年 | 18篇 |
2022年 | 35篇 |
2021年 | 60篇 |
2020年 | 34篇 |
2019年 | 50篇 |
2018年 | 50篇 |
2017年 | 31篇 |
2016年 | 58篇 |
2015年 | 49篇 |
2014年 | 58篇 |
2013年 | 95篇 |
2012年 | 112篇 |
2011年 | 122篇 |
2010年 | 65篇 |
2009年 | 56篇 |
2008年 | 92篇 |
2007年 | 99篇 |
2006年 | 78篇 |
2005年 | 73篇 |
2004年 | 84篇 |
2003年 | 77篇 |
2002年 | 85篇 |
2001年 | 70篇 |
2000年 | 75篇 |
1999年 | 58篇 |
1998年 | 23篇 |
1997年 | 17篇 |
1996年 | 17篇 |
1995年 | 22篇 |
1993年 | 14篇 |
1992年 | 71篇 |
1991年 | 54篇 |
1990年 | 55篇 |
1989年 | 65篇 |
1988年 | 66篇 |
1987年 | 67篇 |
1986年 | 62篇 |
1985年 | 52篇 |
1984年 | 36篇 |
1983年 | 22篇 |
1979年 | 29篇 |
1978年 | 14篇 |
1977年 | 15篇 |
1976年 | 14篇 |
1975年 | 13篇 |
1972年 | 15篇 |
1971年 | 18篇 |
1970年 | 13篇 |
1969年 | 13篇 |
1968年 | 13篇 |
排序方式: 共有2550条查询结果,搜索用时 15 毫秒
61.
62.
Shigeru Okuyama Shigeyuki Yamada Shin-ichi Ogawa Katsuji Shima Katsuo Kamata Kazuyuki Tomisawa 《Neurological research》2013,35(3):300-304
Abstract Objective: The strength–duration time constant (SDTC) is a measure of axonal excitability and it can provide information about Na+ channel function. In this study, we sought to examine the changes in the SDTCs of motor and sensory fibers of the median nerve in patients taking colchicine, which affects axoplasmic flow and may result in axonal neuropathy. Methods and results: The SDTCs of motor and sensory fibers of 29 patients who had been taking colchicine were measured following stimulation of the right median nerve at the wrist. The results were compared with ten healthy age-matched subjects. No significant differences were found between the groups. Conclusions: The lack of any effect on the SDTC by colchicine might have been due to the fact that axonal degeneration caused by colchicine affects the Na+–K+ ATP pump or that it affects internodal channels other than nodal channels. 相似文献
63.
64.
Shima Gholizadeh Emmy M. Dolman Rebecca Wieriks Rolf W. Sparidans Wim E. Hennink Robbert J. Kok 《Pharmaceutical research》2018,35(4):85
Purpose
Sepantronium bromide (YM155) is a hydrophilic quaternary compound that cannot be administered orally due to its low oral bioavailability; it is furthermore rapidly eliminated via the kidneys. The current study aims at improving the pharmacokinetic profile of YM155 by its formulation in immunoliposomes that can achieve its enhanced delivery into tumor tissue and facilitate uptake in neuroblastoma cancer cells.Methods
PEGylated YM155 loaded liposomes composed of DPPC, cholesterol and DSPE-PEG2000 were prepared via passive film-hydration and extrusion method. Targeted (i.e. immuno-)liposomes were prepared by surface functionalization with SATA modified monoclonal anti-disialoganglioside (GD2) antibodies. Liposomes were characterized based on their size, charge, antibody coupling and YM155 encapsulation efficiency, and stability. Flow cytometry analysis and confocal microscopy were performed on IMR32 and KCNR neuroblastoma cell lines. The efficacy of developed formulations were assessed by in-vitro toxicity assays. A pilot pharmacokinetic analysis was performed to assess plasma circulation and tumor accumulation profiles of the developed liposomal formulations.Results
YM155 loaded immunoliposomes had a size of 170 nm and zeta potential of ?10 mV, with an antibody coupling efficiency of 60% andYM155 encapsulation efficiency of14%. Targeted and control liposomal formulations were found to have similar YM155 release rates in a release medium containing 50% serum. An in-vitro toxicity study on KCNR cells showed less toxicity for immunoliposomes as compared to free YM155. In-vivo pharmacokinetic evaluation of YM155 liposomes showed prolonged blood circulation and significantly increased half-lives of liposomal YM155 in tumor tissue, as compared to a bolus injection of free YM155.Conclusions
YM155 loaded immunoliposomes were successfully formulated and characterized, and initial in-vivo results show their potential for improving the circulation time and tumor accumulation of YM155.65.
66.
67.
Tatsuaki Sumiyoshi Yasuo Shima Ritsuo Nishiuchi Kiyoshi Sasaki Akihito Kouzuki Yoshihiro Noda Yasuhiro Hata Kiminobu Uka 《Surgery today》2014,44(6):1138-1141
A 13-year-old boy was referred to us for investigation of a giant liver mass, approximately 16 cm in diameter. Sonographically guided percutaneous needle biopsy was performed and histological examination revealed a fetal-type hepatoblastoma. After four courses of chemotherapy, we performed a left hepatic trisegmentectomy. Follow-up computed tomography, 55 months after the surgery, showed a 1-cm tumor on the route of the preoperative needle biopsy. A second laparotomy revealed a peritonealised tumor, which was excised. The histology of this tumor was identical to that of the primary hepatoblastoma. To our knowledge, this is only the second report of needle tract implantation of hepatoblastoma after percutaneous needle biopsy. 相似文献
68.
K Tsuda Y Minatogawa S Tsuda H Shima I Nishio R Kido Y Masuyama 《Japanese heart journal》1987,28(6):923-931
To investigate the sensitivity to calcium of erythrocytes in hypertension, changes in the osmotic fragility of erythrocytes following Ca-loading were observed. Washed erythrocytes were obtained from spontaneously hypertensive rats (SHR, Okamoto and Aoki) and age-matched normotensive Wistar Kyoto rats (WKY). Treatment of erythrocytes with Ca-ionophore A23187 and Ca in the medium caused a reduction in the osmotic fragility which correlated with the Ca-concentration. The degree of alteration in the osmotic fragility of erythrocytes was greater in SHR than in WKY. Oral administration of hydralazine to SHR significantly reduced the blood pressure. However, the alterations in the osmotic fragility of erythrocytes secondary to Ca-loading were not different between hydralazine-treated and untreated SHR. In the presence of a Ca-antagonist (verapamil or diltiazem) in the medium, the reduction of the osmotic fragility of erythrocytes caused by Ca-loading was inhibited, and the differences between SHR and WKY were abolished by Ca-antagonists. These results suggest that the greater changes in osmotic fragility of erythrocytes caused by Ca-loading in SHR could be due to a genetic abnormality of Ca-handling by the cell membranes, and that this abnormality might cause an increase in intracellular Ca, which contributes, in part, to the pathogenesis of hypertension. 相似文献
69.
Shimizu M Tatsumi K Miwa Y Shima T Okada T Minami H Mukohara N 《Journal of cardiology》2004,43(2):81-86
A 76-year-old man with previous antero-septal myocardial infarction and aorto-coronary bypass surgery developed exertional dyspnea. Echocardiography revealed diffuse left ventricular hypokinesis and aortic stenosis with a mean pressure gradient of 29 mmHg. Coronary angiography showed no significant lesions in the bypass grafts and total occlusions of the proximal left anterior descending artery and mid circumflex artery. Dobutamine stress echocardiography was performed to evaluate the severity of aortic stenosis and left ventricular functional reversibility. Administration of dobutamine increased the mean pressure gradients to 48 mmHg and increased the stroke volume by 28% without change in aortic valve area of about 0.5 cm2. We considered that our patient had severe aortic stenosis with contractile reserve. After aortic valve replacement, he improved with better left ventricular function. 相似文献
70.
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy 总被引:35,自引:6,他引:35
Nishimoto N Sasai M Shima Y Nakagawa M Matsumoto T Shirai T Kishimoto T Yoshizaki K 《Blood》2000,95(1):56-61
Castleman's disease, an atypical lymphoproliferative disorder, can be classified into 2 types: hyaline-vascular and plasma cell types according to the histologic features of the affected lymph nodes. The plasma cell type is frequently associated with systemic manifestations and is often refractory to systemic therapy including corticosteroids and chemotherapy, particularly in multicentric form. Dysregulated overproduction of interleukin-6 (IL-6) from affected lymph nodes is thought to be responsible for the systemic manifestations of this disease. Therefore, interference with IL-6 signal transduction may constitute a new therapeutic strategy for this disease. We used humanized anti-IL-6 receptor antibody (rhPM-1) to treat 7 patients with multicentric plasma cell or mixed type Castleman's disease. All patients had systemic manifestations including secondary amyloidosis in 3. With the approval of our institution's ethics committee and the consent of the patients, they were treated with 50 to 100 mg rhPM-1 either once or twice weekly. Immediately after administration of rhPM-1, fever and fatigue disappeared, and anemia as well as serum levels of C-reactive protein (CRP), fibrinogen, and albumin started to improve. After 3 months of treatment, hypergammaglobulinemia and lymphadenopathy were remarkably alleviated, as were renal function abnormalities in patients with amyloidosis. Treatment was well tolerated with only transient leukopenia. Histopathologic examination revealed reduced follicular hyperplasia and vascularity after rhPM-1 treatment. The pathophysiologic significance of IL-6 in Castleman's disease was thus confirmed, and blockade of the IL-6 signal by rhPM-1 is thought to have potential as a new therapy based on the pathophysiologic mechanism of multicentric Castleman's disease. (Blood. 2000;95:56-61) 相似文献